Completely fair assessment - I remember reading that of the types of nuclear VQ about 2/3 of the markets use V/Q scintigraphy planar imaging which is without a doubt worse than spect & CTVQ - so there's an easy 2/3 of the market which can be obtained
With regards to spect, because of the better workflow/accessibility advantages, higher sparial resolution and lack of artifacts (more common in spect) 4D only needs to show ‘substantial equivalence’ for FDA approval and to convince clinics to switch over.
I still think this is a winner for 4DX and I would be shaking if I was cyc
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $135.0M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.0¢ | 27.5¢ | $309.2K | 1.097M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1754 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 5595 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| 4DX (ASX) Chart |